TGFB1 and neoplasm: Other approaches for inhibiting TGF-β signaling include SMAD7-expressing CAR T-cells (92, 93), and knockout of the endogenous TGF-βRII in CAR T-cells using CRISPR/Cas9 technology (94), both of which improved anti-tumor efficacy in vivo.